Laserscope (NASDAQ LSCP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Laserscope (NASDAQ LSCP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: wpckr who wrote (123)	9/18/1997 11:09:00 PM
From: Feraldo	of 314

Didn't anyone read this. This tells it all. biz.yahoo.com Didn't anyone read this. Espescially this: According to the National Cancer Institute, lung cancer is the leading cause of cancer mortality in the U.S., responsible for more than 150,000 deaths a year. In recent years, the rate of increase in lung cancer has outpaced that of any other major malignancy, rising from 149,000 new cases in 1993 to 177,000 new cases in 1996. Added Mr. McCormick: ``The potential of being able to treat early-stage lung cancer with our portfolio of laser and fiberoptic products adds a new dimension and direction to our business,'' he said. ``Aside from the Laserscope PDT lasers required to activate PHOTOFRIN, each treatment will consume at least one fiberoptic delivery device priced in the $300-$600 range.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next